Short Summary
Entegris and Inpria have settled their dispute over U.S. Patent No. 11,673,903 and jointly moved to terminate the inter partes review. The Board had previously instituted the proceeding but no merits were decided.
Detailed Summary
In IPR2025-00267, petitioner Entegris, Inc. and patent owner Inpria Corp. filed a joint motion to terminate the inter partes review of U.S. Patent No. 11,673,903 under 35 U.S.C. § 317. The parties cite a settlement agreement that resolves all disputes related to the ’903 Patent and argue that public policy and PTAB guidance favor termination after settlement. The Board had instituted the review on February 17, 2026, but the Patent Owner had not yet filed its response. The motion includes a request to keep the settlement confidential. The Board is asked to terminate the proceeding, conserving resources and honoring the parties’ agreement.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Entegris, Inc. vs Inpria Corporation is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
lululemon usa inc. et al.vsNike, Inc.
lululemon challenges Nike's patent claims related to knitting textile structures in footwear manufacturing. The petitioner asserts that numerous claims are anticipated by Nishida and rendered obvious by Zuckerman, seeking invalidation of the '749 patent.
TransCore, LPvsHand Held Products, Inc.
Hand Held Products argues that TransCore’s IPR petition is deficient, lacking proper proof that the cited references qualify as prior art, and seeks denial of institution.
iRhythm, Inc.vsWelch Allyn, Inc. et al.
iRhythm has filed an IPR petition challenging 26 claims of Welch Allyn’s wearable heart‑monitor patent, asserting obviousness over Jensen, Kroll and other prior art. The petition argues no discretionary denial factors apply and seeks cancellation of the claims.
MSN Pharmaceuticals, Inc. et al.vsBreckenridge Pharmaceutical, Inc.
MSN Pharmaceuticals and its Indian affiliate petition PTAB to invalidate 18 claims of Breckenridge’s 2021 dabigatran composition patent, arguing obviousness over Brauns combined with Leane or Sugimoto.
Databricks, Inc.vsByteWeavr LLC
Databricks has filed an IPR petition seeking to invalidate claims 37‑43 of ByteWeavr’s ’733 patent as obvious over Chow, Lee and White. The petition argues that a skilled artisan would combine these references to achieve the claimed agent‑based network functionality.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.